Marilyn Bulloch, PharmD, BCPS, FCCM, SPP

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

As medication experts, pharmacists can aid in treatment selection and support patients through the process.

Phage therapy, which uses lytic bacteriophages to target antibiotic-resistant bacteria, has resurfaced as a promising treatment for multidrug-resistant infections, but faces challenges in regulation, production, and clinical implementation despite its growing evidence of efficacy.

Sixty years after the first hormonal birth control pill was marketed to women, men still have limited options with variable efficacy for birth control.

Results of the ACTIV-6 study showed that high dose ivermectin use did not demonstrate a clinical benefit for mild to moderate COVID-19.

COVID-19 vaccines are known to have one of the most complex schedules that the average pharmacist has ever had to manage for a vaccine directed towards a single preventable disease.

Although pharmacists possess a wealth of knowledge on AEs, it remains a monumental task to recall the clinical significance of every AE, even with the most commonly used medications.

CDC makes groundbreaking shift by providing influenza vaccination recommendations for the geriatric population.